Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a slight decline of 0.12% on December 10, with a trading volume of 27.6345 million yuan, indicating ongoing market volatility in the innovative drug sector [1] Group 1: Fund Performance - The latest net asset value of the Hong Kong Innovative Drug ETF is 588 million yuan [1] - Since its inception on August 20, 2025, the fund has reported a return of -13.25% [1] - Over the past month, the fund's return has been -2.02% [1] Group 2: Fund Management - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang overseeing its operations [1] - The performance benchmark for the fund is the Guozhen Hong Kong Stock Connect Innovative Drug Index return (adjusted for exchange rates) [1] Group 3: Fund Size and Activity - The fund's shares increased by 1 million to a total of 678 million shares, although there has been a reduction of 25 million shares over the last 20 trading days [1]
12月10日港股创新药ETF鹏华（159286）份额增加100.00万份
Xin Lang Cai Jing·2025-12-11 01:13